Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Plasma 1,25-Dihydroxy- And 25-Hydroxyvitamin D And Subsequent Risk Of Prostate Cancer

E. Platz, M. Leitzmann, B. Hollis, W. Willett, E. Giovannucci
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
AbstractObjective: The hormone 1,25-dihydroxyvitamin D (1,25(OH)2D) promotes prostate epithelial cell differentiation in vitro and thus, several groups have hypothesized that men who systemically have lower levels of 1,25(OH)2D may be at increased risk for prostate cancer. To address this hypothesis, we evaluated the association of circulating concentrations of 1,25(OH)2D and its precursor 25-hydroxyvitamin D (25(OH)D) with subsequent risk of prostate cancer. Methods: Prostate cancer cases were 460 men in the Health Professionals Follow-up Study who were diagnosed through 1998 after providing a blood specimen in 1993/95. 90.2% of the cases were organ confined or had minimal extraprostatic extension. An equal number of controls who had had a screening PSA test after blood draw were individually matched to cases on age, history of a PSA test before blood draw, and time of day, season, and year of blood draw. Plasma 1,25(OH)2D and 25(OH)D concentrations were determined by radio-immunosorbant assay blindly to case–control status. Odds ratios (OR) of prostate cancer and 95% confidence intervals (CI) were estimated from conditional logistic regression models mutually adjusting for quartiles of 1,25(OH)2D and 25(OH)D concentrations and for suspected prostate cancer risk factors. Quartile cutpoints were determined separately by season of blood draw using the distributions among controls. Results: Mean concentrations of 1,25(OH)2D and 25(OH)D were slightly, but not statistically significantly (p= 0.06 and 0.20, respectively), higher in cases (34.3 ± 7.1 pg/ml and 24.6 ± 7.7 ng/ml, respectively) than in controls (33.5 ± 7.1 pg/ml and 23.9 ± 8.2 ng/ml, respectively). The OR of prostate cancer comparing men in the top to bottom quartile of 1,25(OH)2D was 1.25 (95% CI: 0.82–1.90, p-trend = 0.16). For 25(OH)D the OR of prostate cancer comparing the top and bottom quartiles was 1.19 (95% CI: 0.79–1.79, p-trend = 0.59). These findings did not vary by level of the other metabolite, age at diagnosis, family history of prostate cancer, or factors that are thought to influence 25(OH)D levels. Conclusion: In this prospective study, we did not observe an inverse association between plasma concentrations of 1,25(OH)2D or 25(OH)D and incident prostate cancer, although we cannot rule out potential effects at later stages of the disease.
This paper references
Inhibition of human prostatic carcinoma cell lines by 1,25 dihydroxyvitamin D3 and vitamin D analogs
RR Bahnson (1993)
Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate.
M. S. Lucia (1995)
10.1210/ENDO.132.5.7682937
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
R. Skowroński (1993)
10.1210/ENDO.137.5.8612485
Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
T. Hedlund (1996)
10.1056/NEJM198904133201506
The role of the vitamin D endocrine system in health and disease.
H. Reichel (1989)
10.1007/BF00051795
Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
M. Braun (2004)
10.1093/OXFORDJOURNALS.AJE.A113804
Test of the National Death Index.
M. Stampfer (1984)
10.1023/A:1008823601897
Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden)
J. Chan (2004)
IGF - binding proteins in human
RH Drivdahl (1995)
10.1006/BBRC.1996.0859
Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells.
T. Hsieh (1996)
Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
G. Miller (1995)
10.1023/A:1008947201132
Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland)
J. Chan (2004)
10.1111/j.1532-5415.1991.tb01615.x
Is the Recommended Daily Allowance for Vitamin D Too Low for the Homebound Elderly?
F. M. Gloth (1991)
tumor cells : expression and regulation by 1 , 25 - dihydroxyvitamin D 3
M Esquenet (1996)
10.1023/A:1008923802001
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
M. Ahonen (2004)
10.1016/S0303-7207(00)00226-4
1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration
Victoria Sung (2000)
10.1093/CLINCHEM/39.3.529
Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer.
B. Hollis (1993)
Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.
D. Peehl (1994)
Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3.
G. Schwartz (1998)
10.1016/S0090-4295(99)80221-0
1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.
G. Schwartz (1995)
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).
G. Schwartz (1990)
10.1207/S15327655JCHN1501_7
Taber's Cyclopedic Medical Dictionary (Book)
Valerie Parham (1998)
10.1002/(SICI)1097-0045(199603)28:3<182::AID-PROS5>3.0.CO;2-H
Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, Iα,25‐dihydroxycholecalciferol, all‐trans retinoic acid, 9‐cis retinoic acid, and phenylacetate
M. Esquenet (1996)
10.1023/A:1008875819232
Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)
A. Nomura (2004)
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.
P. Gann (1996)
Vitamin D and prostate cancer: a prediagnostic study with stored sera.
E. Corder (1993)
10.1093/CLINCHEM/42.4.586
Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer.
B. Hollis (1996)
10.1152/PHYSREV.1980.60.2.551
Regulation of the metabolism of vitamin D.
D. R. Fraser (1980)
Calcium and fructose intake in relation to risk of prostate cancer.
E. Giovannucci (1998)
10.1002/PROS.2990260203
IGF‐Binding proteins in human prostate tumor cells: Expression and regulation by 1,25‐dihydroxyvitamin D3
R. Drivdahl (1995)



This paper is referenced by
10.37421/jcdd.2020.8.406
The Relationship between Plasma Vitamin D Level and Heart Valves Calcification
K. FeldmanViktor (2020)
10.1016/J.ENDONU.2010.01.013
Hiperparatiroidismo secundario en el cáncer de próstata avanzado
Susana Quirosa Flores (2010)
10.3945/ajcn.111.033373
Selenium and prostate cancer: systematic review and meta-analysis.
R. Hurst (2012)
10.1017/S0954422409990151
Epidemiology of vitamin D in health and disease
S. Wang (2009)
10.1146/annurev-nutr-080508-141248
Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer.
M. McCullough (2009)
10.1158/1055-9965.EPI-08-0342
Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis
L. Zuccolo (2008)
10.1158/1055-9965.EPI-18-1083
Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer
N. Khan (2019)
10.1158/1055-9965.EPI-05-0586
A Prospective Study of Calcium Intake and Incident and Fatal Prostate Cancer
E. Giovannucci (2006)
10.1038/pcan.2009.7
Vitamin D and prostate cancer risk: a review of the epidemiological literature
D. Gupta (2009)
10.1038/nrurol.2009.234
Nutraceuticals and prostate cancer prevention: a current review
Greg Trottier (2010)
10.1002/PROS.20570
Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25‐hydroxyvitamin D and 1,25‐dihydroxyvitamin D, and prostate cancer risk
B. Mikhak (2007)
10.1158/1078-0432.CCR-13-3085
Vitamin D Deficiency Predicts Prostate Biopsy Outcomes
A. Murphy (2014)
10.1158/1538-7445.AM10-2805
Cohort Consortium Vitamin D Pooling Project of Rarer Cancers
M. McCullough (2010)
10.1016/j.ucl.2011.04.007
Prostate cancer and vitamin D: what does the evidence really suggest?
C. Barnett (2011)
10.1016/j.bone.2015.11.016
Physical activity, sedentary behavior, and vitamin D metabolites.
Elizabeth A. Hibler (2016)
10.1007/s10552-015-0684-3
Vitamin D, PTH, and calcium and tumor aggressiveness in prostate cancer: a prospective nested case–control study
Johan Brändstedt (2015)
10.3390/nu8030142
Vitamin D and Sunlight Exposure in Newly-Diagnosed Parkinson’s Disease
J. Wang (2016)
10.1097/CCM.0b013e318260c928
Association of low serum 25-hydroxyvitamin D levels and acute kidney injury in the critically ill*
A. Braun (2012)
10.1161/HYPERTENSIONAHA.107.087288
Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension
J. Forman (2007)
10.1080/10937400701873548
Role of Hormonal and Other Factors in Human Prostate Cancer
D. T. Wigle (2008)
10.1017/S0007114507657961
Calcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer.
J. Bonjour (2007)
10.1007/s10552-010-9706-3
Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis
R. Gilbert (2010)
10.1080/01635581.2013.806936
Serum Calcium Concentration and Prostate Cancer Risk: A Multicenter Study
S. Salem (2013)
10.1017/S0954422409990102
Vitamin D in health and disease: an insight into traditional functions and new roles for the ‘sunshine vitamin’
D. Borradale (2009)
10.1201/9781420019131.CH8
Nutrient- and Drug- Responsive Polymorphic Genes as Nutrigenomic Tools for Prevention of Cardiovascular Disease and Cancer
M. Bakovic (2006)
10.3390/nu8050273
Association of Circulating 25(OH)D and Lower Urinary Tract Symptoms: A Four-Year Prospective Study among Elderly Chinese Men
Zhao-min Liu (2016)
10.1093/jnci/djn164
Vitamin D and prostate cancer risk--a less sunny outlook?
L. Mucci (2008)
10.1097/CCM.0b013e31829eb7af
Association of Low Serum 25-Hydroxyvitamin D Levels and Sepsis in the Critically Ill
T. Moromizato (2014)
10.1158/0008-5472.CAN-04-3134
Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer.
E. John (2005)
10.1158/1055-9965.EPI-11-0153
Serum 25-Hydroxyvitamin D and Risk of Oropharynx and Larynx Cancers in Finnish Men
H. Arem (2011)
10.1093/aje/kwq115
Circulating 25-Hydroxyvitamin D and Risk of Kidney Cancer
L. Gallicchio (2010)
10.1158/1055-9965.EPI-07-0672
Lack of Association between Serum Levels of 25-Hydroxyvitamin D and the Subsequent Risk of Prostate Cancer in Finnish Men
J. Faupel-Badger (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar